Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Oct;62(4):627–630. doi: 10.1038/bjc.1990.343

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

J G Klijn 1, A M Hoff 1, A S Planting 1, J Verweij 1, T Kok 1, S W Lamberts 1, H Portengen 1, J A Foekens 1
PMCID: PMC1971491  PMID: 1977468

Abstract

Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995). All patients had an extensive tumour load and 13 were pretreated with chemotherapy. Before Sandostatin treatment the patients with pancreatic cancer showed a higher mean plasma concentration of GH (P less than 0.05) and a lower concentration of 'total' somatomedin-C (P less than 0.005) compared with patients with colorectal cancer; there was no significant difference between these two groups in plasma levels of directly assayable somatomedin-C, EGF/TGF-alpha, insulin and prolactin. Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks. Plasma insulin levels also were suppressed but only during the first 3-5 days of treatment. Plasma EGF-TGF-alpha levels increased significantly at day 5 of treatment only in the pancreatic cancer patients. Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects. However, the overall survival remained disappointing, emphasising the need for better treatment regimens.

Full text

PDF
627

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adrian T. E., Barnes A. J., Long R. G., O'Shaughnessy D. J., Brown M. R., Rivier J., Vale W., Blackburn A. M., Bloom S. R. The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. J Clin Endocrinol Metab. 1981 Oct;53(4):675–681. doi: 10.1210/jcem-53-4-675. [DOI] [PubMed] [Google Scholar]
  2. Chrubasik J., Meynadier J., Blond S., Scherpereel P., Ackerman E., Weinstock M., Bonath K., Cramer H., Wünsch E. Somatostatin, a potent analgesic. Lancet. 1984 Nov 24;2(8413):1208–1209. doi: 10.1016/s0140-6736(84)92761-2. [DOI] [PubMed] [Google Scholar]
  3. Foekens J. A., Portengen H., Janssen M., Klijn J. G. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer. 1989 Jun 1;63(11):2139–2147. doi: 10.1002/1097-0142(19890601)63:11<2139::aid-cncr2820631112>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  4. Foekens J. A., Portengen H., van Putten W. L., Trapman A. M., Reubi J. C., Alexieva-Figusch J., Klijn J. G. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):7002–7009. [PubMed] [Google Scholar]
  5. Johnson L. R. Effects of gastrointestinal hormones on pancreatic growth. Cancer. 1981 Mar 15;47(6 Suppl):1640–1645. doi: 10.1002/1097-0142(19810315)47:6+<1640::aid-cncr2820471430>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  6. Klijn J. G., Lamberts S. W., de Jong F. H., Docter R., Van Dongen K. J., Birkenhäger J. C. The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour. Clin Endocrinol (Oxf) 1980 Apr;12(4):341–355. doi: 10.1111/j.1365-2265.1980.tb02719.x. [DOI] [PubMed] [Google Scholar]
  7. Lamberts S. W., Reubi J. C., Uiterlinden P., Zuiderwijk J., van den Werff P., van Hal P. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology. 1986 Jun;118(6):2188–2194. doi: 10.1210/endo-118-6-2188. [DOI] [PubMed] [Google Scholar]
  8. Lamers C. B., Jansen J. B. Role of gastrin and cholecystokinin in tumours of the gastrointestinal tract. Eur J Cancer Clin Oncol. 1988 Feb;24(2):267–273. doi: 10.1016/0277-5379(88)90264-7. [DOI] [PubMed] [Google Scholar]
  9. Meynadier J., Chrubasik J., Dubar M., Wünsch E. Intrathecal somatostatin in terminally ill patients. A report of two cases. Pain. 1985 Sep;23(1):9–12. doi: 10.1016/0304-3959(85)90224-6. [DOI] [PubMed] [Google Scholar]
  10. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  11. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  12. Reubi J. C., Horisberger U., Essed C. E., Jeekel J., Klijn J. G., Lamberts S. W. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology. 1988 Sep;95(3):760–763. doi: 10.1016/s0016-5085(88)80025-8. [DOI] [PubMed] [Google Scholar]
  13. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  14. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES